148 related articles for article (PubMed ID: 35760571)
1. New approaches in palliative systemic therapy of anal squamous cell carcinoma.
Lohynská R; Pechačová Z
Klin Onkol; 2022; 35(3):190-194. PubMed ID: 35760571
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
[TBL] [Abstract][Full Text] [Related]
4. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
Kim S; Jary M; Mansi L; Benzidane B; Cazorla A; Demarchi M; Nguyen T; Kaliski A; Delabrousse E; Bonnetain F; Letondal P; Bosset JF; Valmary-Degano S; Borg C
Ann Oncol; 2013 Dec; 24(12):3045-50. PubMed ID: 24114858
[TBL] [Abstract][Full Text] [Related]
5. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S
Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
[TBL] [Abstract][Full Text] [Related]
7. [Effects of radical radiotherapy combined with different regimens of chemotherapy on radiation intestinal injury in patients with non-metastatic anal squamous cell carcinoma].
Pang XL; Liu S; Liu YP; Chen HY; He F; Zheng J; Wan XB
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):977-983. PubMed ID: 34823298
[No Abstract] [Full Text] [Related]
8. [Metastatic squamous cell carcinomas of the anal canal: Current management and prospects].
Saint A; Evesque L; François É
Bull Cancer; 2020; 107(7-8):792-799. PubMed ID: 32591138
[TBL] [Abstract][Full Text] [Related]
9. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Khawandanah M; Baxley A; Pant S
J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
[TBL] [Abstract][Full Text] [Related]
10. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
Eng C; Chang GJ; You YN; Das P; Rodriguez-Bigas M; Xing Y; Vauthey JN; Rogers JE; Ohinata A; Pathak P; Sethi S; Phillips JK; Crane CH; Wolff RA
Oncotarget; 2014 Nov; 5(22):11133-42. PubMed ID: 25373735
[TBL] [Abstract][Full Text] [Related]
11. Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Yamasaki M; Sato Y; Okamoto K; Fukuya A; Kawaguchi T; Noda K; Kagemoto K; Mitsui Y; Miyamoto H; Takayama T
Clin J Gastroenterol; 2023 Apr; 16(2):180-186. PubMed ID: 36409453
[TBL] [Abstract][Full Text] [Related]
12. Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients.
Cho BC; Ahn JB; Seong J; Roh JK; Kim JH; Chung HC; Sohn JH; Kim NK
BMC Cancer; 2008 Jan; 8():8. PubMed ID: 18194582
[TBL] [Abstract][Full Text] [Related]
13. Anti-Telomerase CD4
Spehner L; Kim S; Vienot A; François E; Buecher B; Adotevi O; Vernerey D; Abdeljaoued S; Meurisse A; Borg C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957741
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Kua VF; Ismail F; Chee Ee Phua V; Aslan NM
Asian Pac J Cancer Prev; 2013; 14(2):1121-6. PubMed ID: 23621198
[TBL] [Abstract][Full Text] [Related]
17. [Squamous cell anal carcinoma. What's next ?].
Kim S; Spehner L; Cabel L; Bidard FC; Borg C
Bull Cancer; 2021 Jan; 108(1):80-89. PubMed ID: 33423780
[TBL] [Abstract][Full Text] [Related]
18. The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies.
Jácome AA; Morris VK; Eng C
Curr Treat Options Oncol; 2022 Aug; 23(8):1073-1085. PubMed ID: 35666353
[TBL] [Abstract][Full Text] [Related]
19. Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
Abgral R; Le Roux PY; Keromnes N; Rousset J; Valette G; Gouders D; Leleu C; Mollon D; Nowak E; Querellou S; Salaün PY
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1839-47. PubMed ID: 22895863
[TBL] [Abstract][Full Text] [Related]
20. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.
Demirci NS; Aksoy S; Özdemir NY; Erdem GU; Ozcelik M; Tanrikulu E; Eren T; Bozkaya Y; Sahin S; Başol F; Aslan SA; Zengin N; Güllü İ
Curr Med Res Opin; 2017 Mar; 33(3):401-407. PubMed ID: 27817239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
